Although the effect of MLN8237 on CT26-derived tumor growth differs from that of Aurora-A knockdown (Figs. 2A, B and 7A, B), the combination treatment of MLN8237 with anti-IL-16 antibodies enhances its therapeutic efficacy (Fig. 7E). Here, DDX53 is linked to neoplasm.